Invasive Pneumococcal Disease (IPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Invasive Pneumococcal Disease (IPD) is defined as an infection confirmed by the isolation of Streptococcus pneumoniae from a normally sterile site (eg, blood, cerebrospinal fluid, and pleural, joint, or peritoneal fluid but not sputum). Children with pneumococcal infection often present with non-specific symptoms and signs including isolated fever. Certain populations of children are at increased risk of IPD. Children at particularly high risk are those with antibody deficiencies, such as X-linked (Bruton’s) agammaglobulinemia, anatomic or functional asplenia, sickle cell disease, HIV infection, and those with cochlear implants or CSF leak. Children with other chronic illnesses (eg, cardiac, pulmonary, or renal disease and diabetes mellitus) and those receiving chemotherapy or steroids are also at risk. Children in daycare from an early age also have a higher incidence of IPD. Around 10–20% of children with pneumococcal meningitis have underlying comorbidity. The manifestations of IPD are; Bacteremia, Pneumonia, Meningitis, Cellulitis, Sinusitis, Septic arthritis, Peritonitis, Otitis media, and Others. Bacteremia and pneumonia were most common and the pneumonia patients by definition were bacteremic. Otherwise, meningitis was the most common manifestation of IPD (4.9%) while endocarditis/pericarditis was the least common (<1%).
• The incidence of Invasive Pneumococcal Disease (IPD) in any population is affected by geographic location, time of year, serotype prevalence, age, comorbidities, and vaccination status. The highest incidence of the invasive pneumococcal disease occurs in adults ≥65 years of age, in children <2 years of age, and in those with certain underlying conditions, such as HIV infection.

Thelansis’s “Invasive Pneumococcal Disease (IPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Pneumococcal Disease (IPD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Invasive Pneumococcal Disease (IPD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Invasive Pneumococcal Disease (IPD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Invasive Pneumococcal Disease (IPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Invasive Pneumococcal Disease (IPD), Invasive Pneumococcal Disease (IPD) market outlook, Invasive Pneumococcal Disease (IPD) competitive landscape, Invasive Pneumococcal Disease (IPD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)